Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

FDA Issues Boxed Warning for Hydroxyurea & Neutropenia May Occur after Rituximab Treatments

Michele B. Kaufman, PharmD, BCGP  |  August 26, 2015

The FDA has issued a new boxed warning for Droxia (hydroxyurea). Also, according to a new study, RA patients receiving rituximab should be monitored for late-onset neutropenia…

Filed under:Biologics/DMARDsDrug Updates

Hepatitis Reaction with Rituximab Sparks Drug Safety Alert

M.J. Burton, MD, K.L. Winthrop, MD, MSPH, & J.W. Baddley, MD, MPH  |  January 1, 2015

The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation

Filed under:Biologics/DMARDsDrug Updates Tagged with:drugFDAhepatitisrheumatologyrituximabSafetyvirus

ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis

Mary Beth Nierengarten  |  February 1, 2013

Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:ANCA-Associated VasculitiscyclophosphamiderituximabTreatment

Cardiovascular Risks Similar for JAK Inhibitors & bDMARDs

Arthritis & Rheumatology  |  August 26, 2025

Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Arthritis & Rheumatologycardiovascularcardiovascular eventJAK inhibitorsJanus Kinase InhibitorsRA Resource Center

Sjögren’s Disease: More Than Just a Syndrome

Jason Liebowitz, MD, FACR  |  August 26, 2025

A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.

Filed under:ConditionsEULAR/OtherMeeting ReportsSjögren’s Disease Tagged with:dazodalibepEULAR 2025iscalimabsalivary glandsSjögren’s Disease supplement

How to Diagnose Sjögren’s Disease

Samantha C. Shapiro, MD  |  August 26, 2025

Improve your Sjögren’s disease diagnosis. Experts discuss objective testing, seronegative cases, ILD screening & management strategies.

Filed under:ConditionsGuidancePractice SupportSjögren’s Disease Tagged with:biopsyDry eyeDry MouthDysautonomiaFibromyalgiaInterstitial Lung DiseaselymphomasiccaSjögren’s Disease supplementUltrasound

How the Experts Treat Sjögren’s Disease

Samantha C. Shapiro, MD  |  August 26, 2025

With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.

Filed under:Biologics/DMARDsConditionsDrug UpdatesSjögren’s Disease Tagged with:Clinical Practice GuidelinesDry eyeDry MouthfatigueHYDROXYCHLOROQUINEInterstitial Lung DiseaseMethotrexateneuropathyshared decision makingSjögren’s Disease supplement

Guidelines for ILD in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD  |  August 26, 2025

Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Sclero­derma Program, notes that more recent studies have increased our awareness…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceSjögren’s DiseaseSystemic Sclerosis Tagged with:Interstitial Lung Diseaseinterstitial lung disease (ILD)Sjögren’s Disease supplement

Medicare Drug Price Negotiation: What ACR Members Need to Know Ahead of Round Three

From the College  |  August 22, 2025

As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.

Filed under:Legal Updates Tagged with:Medicare Drug Price Negotiation

Case Report: Pulmonary Artery Stenosis Secondary to Granulomatosis with Polyangiitis

Sambhawana Bhandari, MD, & Colin Diffie, MD  |  August 7, 2025

This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitiscase reportFellows Forumgranulomatosis with polyangiitislarge-vessel vasculitisPulmonary Artery StenosisPulmonary Artery Stentingpulmonary hypertension

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 46
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences